Fetal fibronectin as a predictor of spontaneous preterm birth: A European perspective

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 24, Issue 2, 2011, Pages 330-336

  Chandiramani, Manju ^a   Di Renzo, Gian C ^b   Gottschalk, Elisabeth ^c   Helmer, Hanns ^d   Henrich, Wolfgang ^c   Hoesli, Irene ^e   Mol, Ben ^f   Norman, Jane E ^g   Robson, Stephen ^h   Thornton, Steven ⁱ   Shennan, Andrew ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

cost effectiveness; Fetal fibronectin; prediction; spontaneous preterm birth

Indexed keywords

BIOCHEMICAL MARKER; CORTICOSTEROID; FETOPROTEIN; FIBRONECTIN; PLACEBO; PROGESTERONE; UTERUS SPASMOLYTIC AGENT;

ARTICLE; CERVICAL LENGTH MEASUREMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; EUROPE; HIGH RISK PREGNANCY; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RESPIRATORY DISTRESS SYNDROME; RISK ASSESSMENT; TOCOLYSIS; TREATMENT DURATION;

CERVICAL LENGTH MEASUREMENT; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; FETUS; FIBRONECTINS; HUMANS; PREGNANCY; PREMATURE BIRTH; PRENATAL DIAGNOSIS; PROGNOSIS; RISK FACTORS; RUPTURE, SPONTANEOUS;

EID: 78651455006     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2010.496879     Document Type: Article

References (52)

1. March of Dimes White Paper on Preterm Birth. March of Dimes Foundation. New York, 2009. http://www.marchofdimes. com/.
2. Slattery MM, Morrison JJ. Preterm delivery. Lancet 2002; 360:1489-1497.
3. Chandiramani M, Shennan AH. Preterm labour: update on prediction and prevention strategies. Curr Opin Obstet Gynecol 2006;18:618-624. (Pubitemid 44747178)
4. Di Renzo GC, Roura LC. Guidelines for the management of spontaneous preterm labor. J Perinatal Med 2006;34: 359-366. (Pubitemid 44386155)
5. Langhoff-Roos J, Kesmodel U, Jacobsson B, Rasmussen S, and Vogel I. Spontaneous preterm delivery in primiparous women at low risk in Denmark: population-based study. BMJ 2006;332:937-939. (Pubitemid 44365549)
6. Steer P. The epidemiology of preterm labour. BJOG 2005; 112:1-3. (Pubitemid 40313972)
7. Tekesin I, Marek S, Hellmeyer L, et al. Assessment of rapid fetal fibronectin in predicting preterm delivery. Obstet Gynecol 2005;105:280-284. (Pubitemid 40229442)
8. CDC. Preliminary births for 2004. 2005. http://www.cdc.gov/ nchs/product/pubs/pubd/hcstats/prelimbirths04/prelimbirths 10/12/2009.
9. Chandiramani M, Tribe RM, Shennan AH. Preterm labour and prematurity. Obstet Gynaecol Reprod Med 2007;17: 232-237. (Pubitemid 47260725)
10. Ness A, Visintine J, Ricci E, et al. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007;197:426.e1-426.e7. (Pubitemid 47464160)
11. GilesW, Bisits A, Knox M, et al. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol 2000;2:438-444. (Pubitemid 30127360)
12. Lopez RL, Francis JA, Garite TJ, et al. Fetal fibronectin detection as a predictor of preterm birth in actual clinical practice. Am J Obstet Gynecol 2001;182:1103-1106.
13. Goffinet F. Primary predictors of preterm labour. BJOG 2005;112:38-47. (Pubitemid 40313980)
14. Hassan SS, Romero R, Berry SM, et al. Patients with an ultrasonographic cervical length ≤15mm have nearly a 50% risk of early spontaneous preterm delivery. Am J Obstet Gynecol 2000;182:1458-1467. (Pubitemid 30437417)
15. Daskalakis G, Thomakos N, Hatziioannou L, et al. Cervical assessment in women with threatened preterm labor. J Matern Fetal Neonatal Med 2005;17:309-312. (Pubitemid 40992314)
16. Assessment of risk factors for preterm birth. ACOG Practice Bulletin. Number 31. American College of Obstetricians and Gynecologists. Obstet Gynecol 2001;98:709-716.
17. Sonek JD, Iams JD, Blumenfeld M, et al. Measurement of cervical length in pregnancy: comparison between vaginal ultrasonography and digital examination. Obstet Gynecol 1990;76:172-175. (Pubitemid 20227450)
18. Markenson G, Bsat F. Predicting preterm labor. Female Patient 2008;33:19-25.
19. Romero R, Espinoza J, Erez O, et al. The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified? Am J Obstet Gynecol 2006;194:1-9. (Pubitemid 43017768)
20. Goldenberg RL, Mercer BM, Meis PJ, et al. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. Obstet Gynecol 1996;87:643-648. (Pubitemid 26127076)
21. Matsuura H, Hakomori SI. The oncofetal domain of fibronectin defined by the monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci USA 1985;82:6517-6521. (Pubitemid 16230545)
22. Matsuura H, Takio K, Titani K, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigen specificity provided by a glycosylhexapeptide. J Biol Chem 1988;263:3314-3320. (Pubitemid 18072789)
23. Ruoslahti E. Fibronectin and its receptors. Ann Rev Biochem 1988;57:375-413.
24. Lockwood CJ, Senyei AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. New Engl J Med 1991;325:669-674.
25. Feinberg RF, Kliman HJ, Lockwood CJ. Is oncofetal fibronectin a trophoblast glue for human implantation? Am J Pathol 1991;138:537-543.
26. Morrison JC, Allbert JR, McLaughlin BN, et al. Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery. Am J Obstet Gynecol 1993;168:538-542.
27. Inglis SR, Jeremias J, Kuno K, et al. Detection of tumor necrosis factor-α, interleukin-6, and fetal fibronectin in the lower genital tract during pregnancy: relation to outcome. Am J Obstet Gynecol 1994;171:5-10. (Pubitemid 24254410)
28. Iams J, Casal DC, Goodwin TM, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995;173:141-145.
29. Burrus DR, Ernest JM, Veille JC. Fetal fibronectin, interluekin-6, and C-reactive protein are useful in establishing prognostic sub-categories of idiopathic preterm labor. Am J Obstet Gynecol 1995;173:1258-1262.
30. Bartnicki J, Casal D, Kreaden US, et al. Fetal fibronectin in vaginal specimens predicts preterm delivery and very low birth weight infants. Am J Obstet Gynecol 1996;174:971-974. (Pubitemid 26111678)
31. Lockwood CJ, Wein R, Lapinski R, et al. The presence of cervical and vaginal fetal fibronectin predicts preterm delivery in an inner-city obstetric population. Am J Obstet Gynecol 1993;169:798-804. (Pubitemid 23317509)
32. Leeson SC, Maresh MJA, Martindale EA, et al. Detection of fetal fibronectin as a predictor of preterm delivery in high risk asymptomatic pregnancies. Br J Obstet Gynecol 1996;103: 48-53. (Pubitemid 26009923)
33. Morrison JC, Naef RW, Botti JJ, et al. Prediction of spontaneous preterm birth by fetal fibronectin and uterine activity. Obstet Gynecol 1996;87:649-655. (Pubitemid 26127077)
34. Duhig KE, Chandiramani M, Seed PT, et al. Fetal fibronectin as a predictor of spontaneous preterm labour in asymptomatic women with a cervical cerclage. BJOG 2009;116:799-803.
35. Kurtzman J, Chandiramani M, Briley A, et al. Quantitative fetal fibronectin screening in asymptomatic high-risk patients and the spectrum of risk for recurrent preterm delivery. Am J Obstet Gynecol 2009;200:263.e1-263.e6.
36. Peaceman AM, Andrews WW, Thorp JM, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997, 177:13-18. (Pubitemid 27327304)
37. Goldenberg RL, Iams JD, Mercer BM, et al. The preterm prediction study: the value of new vs. standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health 1998;88: 233-238.
38. Shennan A, Jones G, Hawken J, et al. Fetal fibronectin test predicts delivery before 30 weeks of gestation in high risk women, but increases anxiety. BJOG 2005;112:293-298. (Pubitemid 40314003)
39. Bolt LA, Chandiramani M, De Greeff, et al. Does fetal fibronectin testing change patient management in women at risk of preterm labour? Eur J Obstet Gynecol Reprod Biol 2009;146:180-183.
40. Honest H, Bachmann LM, Gupta JK, et al. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 2002; 325:301.
41. Joffe GM, Jacques D, Bemis-Heys R, et al. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol 1999;180:581-586. (Pubitemid 29149131)
42. Abenhaim HA, Morin L, Benjamin A. Does availability of fetal fibronectin testing in the management of threatened preterm labour affect the utilization of hospital resources? J Obstet Gynaecol Can 2005;27:689-694.
43. Groom KM, Liu E, Allenby K. The impact of fetal fibronectin testing for women with symptoms of preterm labour in routine clinical practice within a New Zealand population. Aust NZ J Obstet Gynaecol 2006;46:440-445. (Pubitemid 44309085)
44. NACB Laboratory Medicine Practice Guidelines. Evidencebased practice for POCT reproductive testing. Available: http://www.nacb.org/lmpg/poct/chp13-repro. doc.
45. Institute for Clinical Systems Improvement (ICSI). Institute for Clinical Systems Improvement, editor. Management of labor. Bloomington, MN; 2005.
46. Institute for Clinical Systems Improvement. Fetal fibronectin for the prediction of preterm labor. Bloomington MN: Institute for Clinical Systems Improvement (ICSI); 2000, Technology Assessment Report 47.
47. NICE Guidelines. Antenatal Care: routine care for the healthy pregnant woman. National Collaborating Centre for Womens and Childrens Health. London; 2003.
48. NICE Guidelines. Antenatal Care: routine care for the healthy pregnant woman. National Collaborating Centre for Womens and Childrens Health. London; 2008.
49. Berghella V, Hayes E, Visintine J, et al. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database Syst Rev 2008;(4):CD006843. (Pubitemid 351805233)
50. Honest H, Forbes CA, Duree KH, et al. Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2009;13(43).
51. Farquarhson D, Lange I, MacDonald WA, Morin L, Simard F. SOGC Special report: preterm labour. Society of Obstetricians and Gynaecologists of Canada, Special Report 2005. Society of Obstetricians and Gynaecologists of Canada.
52. Use of Cervical Fetal Fibronectin as a Screening Test for preterm Birth. The RANZCOG Statement C-Obs 26, Australia, November 2008.